Similar articles

• Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.

  Childress AC, Kollins SH, Cutler AJ, Marraffino A, Sikes CR. Childress AC, et al. J Child Adolesc Psychopharmacol. 2017 Feb;27(1):66-74. doi: 10.1089/cap.2016.0002. Epub 2016 May 16. J Child Adolesc Psychopharmacol. 2017. PMID: 27183299 Free PMC article. Clinical Trial.
• Focalin XR for ADHD.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 Mar 23;51(1308):22-4. Med Lett Drugs Ther. 2009. PMID: 19305368 No abstract available.
• Aptensio XR--another long-acting methylphenidate.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2015 Jul 20;57(1473):101-3. Med Lett Drugs Ther. 2015. PMID: 26204039 Review. No abstract available.
• The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder.

  Storebø OJ, Faltinsen E, Zwi M, Simonsen E, Gluud C. Storebø OJ, et al. Clin Pharmacol Ther. 2018 Oct;104(4):606-609. doi: 10.1002/cpt.1149. Epub 2018 Jul 13. Clin Pharmacol Ther. 2018. PMID: 30006934
• [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].

  Golubchik P, Sever J, Weizman A. Golubchik P, et al. Harefuah. 2011 Oct;150(10):788-90, 814. Harefuah. 2011. PMID: 22111124 Review. Hebrew.